Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03803553 · ClinicalTrials.gov registry record · Phase 3
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
A Phase 3 study of Stage III Colon Cancer and Metastatic Colon Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 3
- Study locations
NCT03803553 is a Phase 3 study of Stage III Colon Cancer and Metastatic Colon Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 400 participants, below the 750-participant average among 6 other Stage III Colon Cancer trials with a reported enrollment target (47% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT03803553, a Phase 3 study of Stage III Colon Cancer and Metastatic Colon Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab
Conditions Studied
Interventions
- DRUG FOLFIRI Protocol
- OTHER ACTIVE SURVEILLANCE
- DRUG Nivolumab Protocol
- DRUG Encorafenib/Binimetinib/Cetuximab Protocol
- DRUG Trastuzumab + Pertuzumab
Study Locations (3)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical College - New York
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03803553
The ClinicalTrials.gov registry entry for NCT03803553 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 750-participant average among 6 other Stage III Colon Cancer trials with a reported enrollment target (47% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage III Colon Cancer appearing as the primary indexed condition, and to 5 interventions - of which FOLFIRI Protocol is the first listed.
NCT03803553 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03803553 about?
NCT03803553 is a clinical study titled "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer". This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Bin...
What is the current status of trial NCT03803553?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2020-04-16. Estimated completion is 2027-12.
What conditions does trial NCT03803553 study?
This clinical trial studies the following conditions: Stage III Colon Cancer, Metastatic Colon Cancer.
What interventions are being tested in trial NCT03803553?
The interventions under investigation include: FOLFIRI Protocol (DRUG), ACTIVE SURVEILLANCE (OTHER), Nivolumab Protocol (DRUG), Encorafenib/Binimetinib/Cetuximab Protocol (DRUG), Trastuzumab + Pertuzumab (DRUG).
Who is sponsoring clinical trial NCT03803553?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03803553 being conducted?
This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
COMPLETED · Phase 3
-
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
RECRUITING · Phase 2
-
Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
RECRUITING · Phase 2
-
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
COMPLETED · Phase 1
-
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
COMPLETED · Phase 1
-
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.